IGHE and nasal cavity polyp: The most cited article is “Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials.” The five most explosive keywords are: expression (5.03), placebo-controlled trial (3.68), anti-IgE (3.35), anti-IgE antibody (3.22), and phenotypes (4.55).